AbbVie (ABBV) Proxy filing summary

Executive summary

• The 2026 Annual Meeting will be held virtually on May 8, 2026, with voting on director elections, auditor ratification, executive compensation, a management proposal to eliminate supermajority voting, and a shareholder proposal on board leadership.

• The company reported strong 2025 results: $61.2B in net revenues (+8.5% operational growth), $19.0B in operating cash flow, and significant R&D investment of $13.8B.

• Market capitalization increased by $309B over the past decade, with a 485% total stockholder return and a 204% increase in quarterly dividends.

• The company continues to advance its pipeline, achieving regulatory approvals and expanding through collaborations and acquisitions.

Voting matters and shareholder proposals

• Four directors are up for election to serve until 2029.

• Ratification of Ernst & Young LLP as independent auditor for 2026 is recommended.

• Advisory vote on executive compensation (say-on-pay) is recommended for approval.

• Management proposes eliminating supermajority voting requirements in the charter and by-laws, moving to a simple majority.

• A shareholder proposal requests an independent board chair; the board recommends voting against it.

Board of directors and corporate governance

• The board consists of 13 directors, 12 of whom are independent; recent refreshment added four new directors since 2023.

• Board leadership structure combines CEO and chair roles, with a robust lead independent director.

• Annual board and committee self-assessments and succession planning are conducted.

• Board diversity: 38% female, 15% ethnically or racially diverse.

• Proxy access by-law allows 3%/3-year holders to nominate directors.